LIGAND PHARMACEUTICALS INC
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $268.1 | $167.1 | $131.3 | $196.2 | $241.5 |
| Operating income | $41.0 | -$22.6 | $11.9 | $3.0 | $103.9 |
| Net income | $124.5 | -$4.0 | $52.2 | -$33.4 | $57.1 |
| Cash Flow Statement | |||||
| Free cash flow | $48.9 | $95.2 | $46.1 | $119.9 | $70.0 |
| Share repurchases | $15.0 | $0.0 | $0.0 | $0.0 | $0.0 |
Shares outstanding 19.9M · Free float 95.6%
Annual filing data through FY ended December 31, 2025; float as of October 8, 2026.
Earnings
Other Coverage
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
September 25, 2026
Deals
Ligand to Invest Up to $47 Million in AvenCell
September 23, 2026
Deals
Ligand to Buy Santen's Ryjunea for $23 Million
August 14, 2026
Industry Earnings Roundup
Healthcare Earnings: Demand Surges, Costs Bite Back
July 15, 2026
Deals
Ligand Completes $739 Million All-Cash Acquisition of XOMA Royalty
June 22, 2026
Earnings Digest
Bitmine Hits $10.7B Treasury; Booz Allen Expands Defense Tech